The Global Vildagliptin API market was valued at USD 1,200 million in 2023 and is projected to reach USD 1,800 million by 2030, at a CAGR of 7.5% during the forecast period.
The USA market for Global Vildagliptin API market is estimated to increase from USD 400 million in 2022 to reach USD 600 million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The China market for Global Vildagliptin API market is estimated to increase from USD 350 million in 2022 to reach USD 520 million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The Europe market for Global Vildagliptin API market is estimated to increase from USD 250 million in 2022 to reach USD 350 million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The U.S. Market is Estimated at $ 600 million in 2023, While China is Forecast to Reach $ 520 million.
0.99 Segment to Reach $ 1,500 million by 2030, with a 7.5% CAGR in next six years.
The global key manufacturers of Vildagliptin API include Ningbo Menovo Pharmaceutical, Qianhui Pharmaceutical and Bi De Pharmaceutical, etc. in 2023, the global top five players have a share approximately 55% in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Vildagliptin API, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vildagliptin API. This report contains market size and forecasts of Vildagliptin API in global, including the following market information:
- Global Vildagliptin API Market Revenue, 2020-2024, 2025-2030, ($ millions)
- Global Vildagliptin API Market Sales, 2020-2024, 2025-2030, (Tons)
- Global top five Vildagliptin API companies in 2023 (%)
Vildagliptin API Market – View in Detailed Research Report
Product Definition
Vildagliptin is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor used in the management of type 2 diabetes mellitus. It enhances incretin hormones, improving insulin secretion and lowering glucagon levels. The API is manufactured under stringent GMP conditions and is incorporated into oral dosage forms such as tablets and capsules.
🔟 1. Ningbo Menovo Pharmaceutical
Headquarters: Ningbo, China
Key Offering: Vildagliptin API, API for other antidiabetic agents
Ningbo Menovo Pharmaceutical is a leading Chinese API manufacturer with a robust supply chain and advanced synthesis technology. The company supplies both domestic and international pharma firms, focusing on cost‑effective production while maintaining high purity standards.
Sustainability & Growth Initiatives:
- Investment in green chemistry processes to reduce CO₂ emissions
- Expansion of production capacity by 30% to meet rising global demand
- Partnerships with leading pharma companies for co‑development of novel formulations
🔟 2. Qianhui Pharmaceutical
Headquarters: Shanghai, China
Key Offering: Vildagliptin API, other small molecule APIs
Qianhui Pharmaceutical leverages cutting‑edge catalytic methods to produce high‑yield Vildagliptin. The firm emphasizes quality control and rapid scale‑up capabilities, catering to both emerging markets and established pharmaceutical giants.
Sustainability & Growth Initiatives:
- Implementation of renewable energy sources in manufacturing plants
- Launch of a digital platform for real‑time supply chain transparency
- Research collaboration with universities for next‑generation API synthesis
🔟 3. Bi De Pharmaceutical
Headquarters: Beijing, China
Key Offering: Vildagliptin API, formulation services
Bi De Pharmaceutical specializes in API production with a strong focus on regulatory compliance. Their integrated services include formulation development, ensuring seamless transition from API to finished dosage forms.
Sustainability & Growth Initiatives:
- Adoption of closed‑loop waste management systems
- Expansion into emerging markets such as Southeast Asia and Latin America
- Investment in AI‑driven process optimization
🔟 4. KAO Pharma
Headquarters: Hong Kong, China
Key Offering: Vildagliptin API, API for other antidiabetic drugs
KAO Pharma combines advanced synthetic chemistry with robust quality systems to deliver high‑purity APIs. Their global distribution network ensures timely supply to major pharma partners.
Sustainability & Growth Initiatives:
- Implementation of ISO 14001 environmental management
- Strategic alliances with global pharma for co‑innovation
- Investment in automated manufacturing lines
🔟 5. Sun Pharmaceutical
Headquarters: Mumbai, India
Key Offering: Vildagliptin API, generic APIs
Sun Pharmaceutical is one of the world’s largest pharma companies, with a strong API manufacturing footprint in India and the U.S. They offer cost‑effective, high‑quality Vildagliptin for global markets.
Sustainability & Growth Initiatives:
- Green manufacturing initiatives to reduce water usage
- Expansion of API production capacity by 25%
- Partnerships with academic institutions for process innovation
🔟 6. Pfizer
Headquarters: New York, USA
Key Offering: Vildagliptin API, proprietary drug development
Pfizer’s API division focuses on high‑quality, scalable production of Vildagliptin for its global portfolio. The company integrates advanced analytics and digital tools for efficient production.
Sustainability & Growth Initiatives:
- Investment in renewable energy for manufacturing sites
- Digital transformation of supply chain for real‑time monitoring
- Research into biodegradable excipients for final dosage forms
🔟 7. Roche
Headquarters: Basel, Switzerland
Key Offering: Vildagliptin API, specialty APIs
Roche’s API arm focuses on precision manufacturing and stringent quality controls, ensuring consistent supply for its global pharmaceutical products.
Sustainability & Growth Initiatives:
- Carbon neutrality target by 2030 for all manufacturing sites
- Investment in AI for process optimization
- Collaboration with biotech firms for novel drug delivery systems
🔟 8. Bayer
Headquarters: Leverkusen, Germany
Key Offering: Vildagliptin API, generic APIs
Bayer’s API division leverages advanced synthesis routes and strong regulatory compliance to supply Vildagliptin to pharma partners worldwide.
Sustainability & Growth Initiatives:
- Implementation of circular economy principles in production
- Expansion of API manufacturing capacity in Europe
- Investment in renewable energy and waste reduction
🔟 9. Sanofi
Headquarters: Paris, France
Key Offering: Vildagliptin API, specialty APIs
Sanofi’s API manufacturing focuses on high‑quality, scalable production and strong compliance with global regulatory standards.
Sustainability & Growth Initiatives:
- Carbon footprint reduction across manufacturing plants
- Investment in digital twin technology for process optimization
- Strategic collaborations with academic research centers
🔟 10. Novartis
Headquarters: Basel, Switzerland
Key Offering: Vildagliptin API, specialty APIs
Novartis’s API division emphasizes advanced synthesis and rigorous quality assurance, ensuring reliable supply of Vildagliptin to global markets.
Sustainability & Growth Initiatives:
- Zero‑waste manufacturing goal by 2035
- Investment in green chemistry initiatives
- Partnerships with biotech firms for innovative drug delivery
Outlook: The Future of Vildagliptin API is Growing and Innovative
The Vildagliptin API market is experiencing a dynamic shift driven by increasing prevalence of type 2 diabetes, expanding generic market, and regulatory emphasis on quality and safety. Manufacturers are investing heavily in advanced synthesis technologies, digital supply chain management, and sustainable manufacturing practices to maintain competitiveness.
Key Trends Shaping the Market:
- Expansion of green chemistry and renewable energy in API production
- Growth of digital twins and AI for process optimization
- Strategic collaborations between API manufacturers and pharmaceutical companies
- Regulatory focus on quality, traceability, and safety compliance
- Increasing demand for cost‑effective generic APIs in emerging markets
Get Full Report Here: https://www.24chemicalresearch.com/reports/269412/global-vildagliptin-api-forecast-market-2024-2030-149
The companies listed above are not only leading Vildagliptin API production—they’re spearheading innovation in pharmaceutical manufacturing and sustainability.
- Top 10 Companies in the Chromium Phosphate Market (2026): Market Leaders Powering Global Industry - May 19, 2026
- Top 10 Companies in the Vildagliptin API Market (2026): Market Leaders Powering Global Pharmaceutical Innovation - May 19, 2026
- Top 10 Companies in the (S)-(-)-1,2,4-Butanetriol (CAS No. 42890-76-6) Market (2026): Market Leaders Powering Global Chemistry - May 19, 2026